BioCryst Pharmaceuticals BCRX License and other revenues — Collaboration revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
Revenue allocated to the license was recognized upon execution of the Neopharmed License Agreement, when control of the Navenibart Licensed Product in Europe transferred to Neopharmed. Revenue allocated to the research and development services is recognized over time using an input method based on costs incurred. During the three and six months ended June 30, 2026, the Company recognized $55,729 of revenue, comprised of $54,513 related to the delivery of the license and $1,216 related to the performance of research and development services in license and other revenues in the Condensed Consolidated Statements of Comprehensive Income (Loss). As of June 30, 2026, the deferred revenue related to the upfront payment was $14,271, of which $7,469 is classified as current and $6,802 is classified as non-current in the Condensed Consolidated Balance Sheet.
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's license and other revenues — collaboration revenue?
- BioCryst Pharmaceuticals (BCRX) reported license and other revenues — collaboration revenue of $54.51M in Q2 2026.
- What does license and other revenues — collaboration revenue mean?
- This metric represents revenue generated from strategic partnerships, including upfront payments, milestone achievements, and royalty income derived from licensing intellectual property to third parties. It reflects the company's ability to monetize its research and development pipeline by leveraging external partners for drug commercialization or clinical advancement. This revenue stream is critical for assessing the success of the company's business development strategy and its ability to supplement core product sales with non-dilutive capital.
Ask your AI about BioCryst Pharmaceuticals's license and other revenues — collaboration revenue.
Connect your AI assistant and compare it to peers, right in your chat.
